Abstract
Before 2003, diagnostic amniocentesis and other invasive procedures were not performed in most eligible pregnant HIV-infected patients because of concern over the risk of mother-to-fetus transmission of the virus. With the introduction and widespread use of antiretroviral therapy (especially HAART), the resulting marked decline in the overall vertical transmission rate in HIV-infected pregnancies led to reappraisal of the actual risk of amniocentesis in a clinical setting. This single center retrospective study evaluated the risk of vertical transmission in 18,191 pregnant women seen at an antenatal clinic from 2001 to 2006. A total of 1168 amniocenteses were performed. Among the 18,191 deliveries during the study period, 330 were by mothers (1.8%) infected with HIV who gave birth to 318 live-born babies. There had been an indication for diagnostic amniocentesis in 34 (10.4%) of the HIV-infected mothers. Amniocentesis was performed in 11 (32.4%) of the eligible women and withheld in 23 (67.6%). Nine of the 11 delivered by mothers who had an amniocentesis were live-born. Demographic profiles and indications for amniocentesis were similar in the 2 groups. During pregnancy and the intrapartum period, all amniocentesis patients had been treated with highly active antiretroviral combination therapy (HAART) with 3 drugs. None of the live-born babies of HIV-infected mothers who underwent amniocentesis were infected with HIV. Among the 19 live-born babies of HIV-infected mothers who did not have an amniocentesis, 1 (5.3%) was positive for HIV. No significant differences were found in vertical transmission rates between the babies live-born to HIV-infected pregnant women with and without an indication for amniocentesis [1/28 (3.6%) vs. 8/290 (2.8%), respectively; P = 0.80]. There was also no difference in transmission rates between patients who had an amniocentesis and those in whom an amniocentesis was considered but withheld [0/9 vs. 1/19 (5.3%); P = 0.48]. The investigators believe that these findings, together with data from previous studies, suggest that diagnostic amniocentesis should not be systematically withheld on the basis of HIV infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have